Adjuvant treatment in biliary tract cancer

Biliary tract cancers (BTC) comprise a heterogeneous group of malignancies arising along the biliary tree with a low incidence and poor prognosis. BTC account for nearly 3% of all gastrointestinal cancers (1) and are classified according to anatomical location into intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma, also known as Klatskin tumor (pCCA) and distal extrahepatic cholangiocarcinoma (eCCA). Despite having a different biological behavior and prognosis, ampullary and gallbladder cancers are grouped with cholangiocarcinoma (CCA) in some series